Medicinal Cannabis Agency - Fees for product assessments

If you hold a medicinal cannabis licence with a ‘supply’ activity (or for CBD products, a relevant Medicines Act licence), you will need to apply to the Medicinal Cannabis Agency for a product assessment for any:

  • medicinal cannabis products (including CBD products) intended for use by patients
  • cannabis-based ingredients (including CBD products)
  • starting material for export

The purpose of the assessment is to verify the product meets the medicinal cannabis minimum quality standard or is exempt from meeting the standard.

The product assessment must be completed, and the product must be specified on your licence, before you can make the product available for supply or export.

See the Guideline on the Regulation of Medicinal Cannabis in New Zealand Part 3: Guidance for medicinal cannabis product assessment applications for detailed information on product assessments.

Application fees for product assessments

The Medicinal Cannabis Agency has set the application fee for a new medicinal cannabis product assessment application to reflect the cost of processing applications.

All application fees are in New Zealand dollars and inclusive of GST. Fees cannot be refunded if an application is withdrawn or declined.

New medicinal cannabis product assessment fees

Fee for initial checking

Upon receipt of your application, the Medicinal Cannabis Agency will issue an invoice for an initial check of the application. The purpose of the check is to ensure your application appears to have been completed in full and is ready for assessment.

The fee for the initial check is $345 including GST and is non-refundable. The initial check will not be carried out until the invoice has been paid.

Once your application has passed the initial check, the Medicinal Cannabis Agency will issue an invoice for an assessment of your new medicinal cannabis product application.

The following table lists fees for assessment of a starting material, cannabis-based ingredient (CBI) or medicinal cannabis product.

Fees for product assessments

The table below lists the fees for product assessments.

* includes an assessment of a cannabis-based ingredient within the finished product.

What is assessed Assessment fee
 (including GST)
Consignment of starting material for export $6,037.50
Cannabis-based ingredient $7,705.00
Dried product $7,705.00
Dosage product only (where CBI has been verified) $7,705.00
Dosage product (includes assessment of CBI) $15,410.00

Changed medicinal cannabis product assessment fees

Fee for initial checking

Upon receipt of your application, the Medicinal Cannabis Agency will issue an invoice for an initial check of the application. The purpose of the check is to ensure your application appears to have been completed in full and determines the complexity of the change.

The fee for the initial check is $345 including GST and is non-refundable. The initial check will not be carried out until the invoice has been paid.

Once your application has passed the initial check, the Medicinal Cannabis Agency will issue an invoice for the appropriate fee for the assessment of changes to your medicinal cannabis product.

Change application categories and fees

The fees for assessing changes to a medicinal cannabis product or cannabis-based ingredient are the application assessment fees set out in regulation 36 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. As per regulation 34(6), the Agency is partially waiving these fees to better reflect an estimate of the complexity and the work required to assess each change.

The following table lists the different change categories and associated fees. If you have multiple changes, a fee will be charged for each change. You will be invoiced for the combined total.

Category Type   Complexity of Change Assessment fee
 (including GST)
1 Low $759.00
2 Medium $1389.00
3 High $2415.00

Further information on the change categories and applicable fees can be found in the: Guideline on The Regulation of Medicinal Cannabis in New Zealand Part 5: Guidance for a Changed Medicinal Cannabis Product Application.

Back to top